Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. (February 2019)

• Record Type: Journal Article
• Authors: Mai, Shijie; Xiong, Gang; Diao, Dingwei; Wang, Wenjing; Zhou, Yujie; Cai, Ruijun
• Is Part Of: Lung cancer. Volume 128(2019)
• Page Start: 101
• Page End: 104
• Publication Date: 2019-02
• Subjects: IMT inflammatory myofibroblastic tumor -- ALK anaplastic lymphoma kinase -- IHC immunohistochemistry -- NGS next-generation sequencing -- NSCLC non-small-cell lung carcinoma -- CT computed tomography -- FISH fluorescence in situ hybridization; Inflammatory myofibroblastic tumor -- ROS1 -- Crizotinib -- Next-generation sequencing; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2018.12.016
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Inflammatory myofibroblastic tumor(IMT) is a rare disease with limited therapeutic options. ROS1 rearrangements have been reported in 9–13% of IMT. We described a boy with ROS1 -rearranged pulmonary IMT who achieved continuous remission with crizotinib. Next generation sequencing provides comprehensive genetic characteristics and potential actionable targets in IMT. Abstract: Objectives: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor and is prevalent among children and adolescents. In recent years, following the emergence of high-throughput sequencing techniques, rearrangements in genes, such as ALK, ROS1, NTRK, RET, and PDGFRβ, have been detected in a considerable proportion of IMT patients. However, the practice of targeted therapy for those patients remains extremely limited. In this study, we report about a 14-year-old boy diagnosed with pulmonary IMT with a mass measuring 12 × 8 cm in the right lower lobe. Materials and methods: Immunohistochemistry (IHC) assay and comprehensive next-generation sequencing (NGS) were performed on the biopsied tumor tissue. Results: The IHC assay revealed an ALK-negative tumor, while NGS detected a TFG-ROS1 rearrangement. The patient achieved continuous remission after treatment with crizotinib (250 mg, bid). Conclusion: This case broadens the experience regarding targeted therapy for ROS1 -rearranged IMT and supports the use of broad molecular profiling testing for optimizing therapeutic options.